Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742430 | 0.84 | GPR35 (0.50) | SMN1; SMN2ALDH1A1KDM4ETDP1KMT2A | |
| SCHEMBL13241715 | 0.81 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL19742415 | 0.81 | TDP1 (0.42) | HSD17B10LMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL29352684 | 0.81 | ALDH1A1 (0.50) | HSD17B10LMNAALDH1A1VCAM1TDP1 | |
| SCHEMBL19742529 | 0.81 | ALDH1A1 (0.50) | HSD17B10LMNAALDH1A1VCAM1TDP1 | |
| SCHEMBL27599828 | 0.78 | HSD17B10 (0.58) | HSD17B10SMN1; SMN2LMNAALDH1A1VCAM1 | |
| SCHEMBL863249 | 0.78 | HSD17B10 (0.62) | HSD17B10SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL19742534 | 0.77 | VCAM1 (0.49) | SMN1; SMN2LMNAALDH1A1VCAM1TDP1 | |
| SCHEMBL4513265 | 0.77 | HSD17B10 (0.56) | HSD17B10SMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL2182437 | 0.76 | HSD17B10 (0.60) | HSD17B10SMN1; SMN2LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109562111-B | CK2 inhibitors, compositions and methods thereof | 北极星药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | HSD17B10 3525/4885SMN1; SMN2 3359/4885LMNA 2774/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | HSD17B10 3525/4885SMN1; SMN2 3359/4885LMNA 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.